Your task is to predict the verdict of a claim based on the provided question-answer pair evidence. The possible labels are: 'Supported', 'Refuted', 'Not Enough Evidence', 'Conflicting Evidence/Cherrypicking'. Justify your answer using the provided evidence and select the correct label.

Claim: Beta-Propiolactone is in vaccines and is known to cause cancer, suspected gastrointestinal, liver, nerve and respiratory, skin and sense organ poison.

Q1: Is Beta-Propiolactone in vaccines?
A1: Yes, because What you need to know before you receive Flucelvax Tetra

beta-propiolactone, cetyltrimethylammonium bromide, or polysorbate 80, which are trace
residues from the manufacturing process.

Q2: How does beta-propiolactone get into vaccines?
A2: beta-Propiolactone is used for vaccines, tissue grafts, surgical instruments, and enzymes, as a sterilant of
blood plasma, water, milk, and nutrient broth, and as a vapor-phase disinfectant in enclosed spaces.

Q3: What side effects can Beta-Propiolactone cause?
A3: Acute Effects:
Acute inhalation exposure beta-propiolactone causes severe irritation of the eyes, nose, throat, and
respiratory tract in humans.  Acute dermal exposure may cause irritation of the skin, blistering, or burns in
humans.  Contact with the eyes may cause permanent corneal opacification. Burns of the mouth and
stomach may occur in humans following acute exposure via ingestion. (1,2)
Acute oral exposure has been observed to result in muscular spasms, respiratory difficulty, and convulsions
at high levels in rats.  In rats acutely exposed intravenously, liver and kidney tubular damage has been
reported. (1,3)
Acute animal exposure tests in rats have demonstrated beta-propiolactone to have extreme acute toxicity
by inhalation. (4)

Chronic Effects (Noncancer):
No information is available on the chronic health effects of beta-propiolactone in humans.
Chronic dermal exposure has resulted in skin irritation, scarring, and hair loss in mice. (1,3)
EPA has not established a Reference Concentration (RfC) or a Reference Dose (RfD) for betapropiolactone.(2)

Reproductive/Developmental Effects:
No information is available on the reproductive or developmental effects of beta-propiolactone in humans
or animals.

Cancer Risk:
No information is available on the carcinogenic effects of beta-propiolactone in humans.
Squamous cell carcinomas of the forestomach have been reported in orally exposed rats. (1,6,8)
In several studies of rats and mice exposed to beta-propiolactone via subcutaneous injection, local tumors
have been observed at the site of injection.  Lymphomas and hepatomas have been reported in mice
following intraperitoneal injection. (1,6,8)
In mice, hamsters, and guinea pigs dermally exposed, skin tumors have been observed. (1,6,8)
EPA has not classified beta-propiolactone for carcinogenicity. (2)
IARC has classified beta-propiolactone as a Group 2B, possible human carcinogen. (6)
user
justification: The answers and source show that the chemical can cause these symptoms in lab animals but no in humans so the claim is cherry picking.

verdict: 'Conflicting Evidence/Cherrypicking'
assistant